TAK - Takeda Entyvio subcutaneous version wins FDA nod
2023-09-27 16:57:55 ET
More on Takeda Pharmaceutical
- Takeda: Innovative But Volatile, Fairly Priced For The Risk (Downgrade)
- ImmunoGen inks deal with Takeda for cancer drug Elahere
- Takeda pulls marketing application for dengue vaccine in the U.S.
- Seeking Alpha’s Quant Rating on Takeda Pharmaceutical
For further details see:
Takeda Entyvio subcutaneous version wins FDA nod